PDPN and neoplasm: According to Tebcherani et al., only 6% of 307 examined BCCs were immunoreactive to podoplanin, with 4% of cases exhibiting a peripheral layer of tumor cell nests reactivity and 2% of cases exhibiting widespread tumor cell podoplanin expression [30].